Navigation Links
Boston Scientific Announces European Approval and Market Launch of New Family of Advanced Pacemakers
Date:5/7/2008

NATICK, Mass., May 7 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced CE Mark approval and market launch of its ALTRUA(TM) family of pacemakers. ALTRUA is Boston Scientific's most advanced pacemaker and delivers enhanced therapies while maintaining its small size and battery longevity. It is the first Boston Scientific-branded pacemaker to treat bradycardia, a condition in which the heart beats too slowly -- usually less than 60 beats per minute -- depriving the body of sufficient oxygen.

"European approval of Boston Scientific's ALTRUA family of pacemakers is the latest example of the significant progress we have made rebuilding our CRM organization and reinvigorating our product pipeline," said Fred Colen, Executive Vice President, Operations and Technology, CRM. "ALTRUA's innovative technology -- enabling physicians to adjust the therapy to meet the needs of their patients -- demonstrates our renewed focus on treating bradycardia."

The ALTRUA pacemaker provides physicians with a number of diagnostic and therapeutic capabilities that enable them to tailor the therapy to specific patient requirements:

-- Multiple Atrial Ventricular (AV) Delay programming options: These

options are designed to reduce unnecessary right ventricular (RV)

pacing, without dropping ventricular beats, a key distinction from

other competitive RV pacing algorithms. The ALTRUA 50 and 60 series

also include an enhanced AV search hysteresis feature, now with an

extendable AV delay out to 400 milliseconds, providing physicians with

additional flexibility to tailor device programming for unique patient

needs.

-- Minute Ventilation (MV) Bl
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents
2. Fraunhofer and Boston University Hosted Prestigious SME Tour
3. Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection
4. Boston Scientific Announces Results for First Quarter Ended March 31, 2008
5. Angiotechs Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System
6. Boston Scientific Receives Canadian Approval for TAXUS(R) Liberte(R) Stent System
7. Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement
8. Boston Scientific and Surgi-Vision Announce Licensing Agreement for MRI-Safe Technology
9. Boston Scientific Announces Japanese Approval of Heart Failure Lead
10. Boehringer Ingelheim and BioSpace Search for Scientists at Career Fair in Boston, Massachusetts
11. Boston Scientific to Webcast Conference Call Discussing First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Antonio, TX (PRWEB) August 29, 2014 ... and ISO 13485:2003 certified, GAMP® 5 compliant imaging ... awarded an international Phase II clinical trial to ... lymphoma. , Throughout this trial, Intrinsic Imaging will ... not limited to, protocol and charter development, site ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and ... 150 ppb,” said Mark Tess, PhD, Mycotoxin Product Manager for ... owners and USDA-GIPSA inspection agencies that have a need to ... place in a matter of minutes with nothing but our ... feed and grain before accepting it, but they no longer ...
(Date:8/28/2014)... August 28, 2014 The ability for ... culture that will allow individuals to perform at the ... important for employers looking to compete in this post–recession ... embracing this trend, as the sector increasingly focuses on ... company, which will have real results on the organization's ...
(Date:8/28/2014)... Aug. 28, 2014  Armetheon, Inc. ( www.armetheon.com ... mid- to late-stage cardiovascular drug candidates, today announced ... first round of financing. The Series A round ... Bioventures with participation from investors that included Atheneos ... Dr. Larry Hsu , the founder of ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... China, FORT LAUDERDALE, Fla., Sept. 5 ... pioneer in laser,optical breast cancer imaging systems, has ... Tianjin Medical University,s Cancer Institute and,Hospital, the largest ... http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO ) Research at the Cancer ...
... EDMONTON, Sept. 5 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: ... of three-year survival results,from a randomized Phase II ... lung cancer (NSCLC). The results suggest that Stimuvax,combined ... benefits to,patients with unresectable stage IIIB NSCLC who ...
... FRANCISCO, Calif., Sept. 5 Hyperion,Therapeutics, a biopharmaceutical ... and hepatology therapies for the,treatment of Urea Cycle ... $40 million Series B financing. Leading the round ... Partners and,NEA, all of Menlo Park, CA. WRF ...
Cached Biology Technology:Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System 2Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System 3Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer 2Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer 3Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer 4Hyperion Therapeutics Secures $40 Million In Series B Round 2
(Date:8/28/2014)... than traditional cigarettes, but still release toxins into ... USC. , Scientists studying secondhand smoke from e-cigarettes ... harmful particles, with close-to-zero exposure to organic carcinogens. ... in second-hand e-cigarette smoke were found to be ... levels of polycyclic aromatic hydrocarbons cancer-causing organic ...
(Date:8/28/2014)... groups and clinicians is critical to the development ... of Georgia research. , A qualitative study of ... that role models for successful breastfeeding help positively ... "Mothers who received that support are more likely ... Alex Anderson, an associate professor in the College ...
(Date:8/28/2014)... complex systems. Their infrastructure equipment requires ancillary sub-systems ... to supply fuel, and ICT systems for control ... is interconnected with a wider network and they ... scientists has studied various aspects of inter-network dependencies, ... in EPJ B by Gaihua Fu from Newcastle ...
Breaking Biology News(10 mins):Second-hand e-cig smoke compared to regular cigarette smoke 2Breastfeeding study shows need for effective peer counseling programs 2Inter-dependent networks stress test 2
... by Dr. Ann F. Jacobson, associate professor in Kent ... may initially choose to postpone but ultimately undergo total ... patient education before and after the procedure. ... pre-and post operative experiences with total knee replacement surgery, ...
... release is available in Spanish . , A ... (USA) and Nakai (China), among others, have deciphered for the first ... to the cover of the last issue of the prestigious journal ... to the group of Molecular Genetics of the Department of ...
... fund four faculty research projects for spring 2008. ... a number of excellent proposals submitted in response ... for the program is administered by the OSU ... by royalties from OSU-licensed technologies. These funded projects ...
Cached Biology News:Research examines factors in delaying or declining total knee replacement surgery 2Scientists decipher fruit tree genome for the first time 2Scientists decipher fruit tree genome for the first time 3OSU technologies funded for development 2OSU technologies funded for development 3
... Maxi MB (for aqueous, other low volatility ... systems respond to specific applications of molecular ... concentration of heat-labile samples. The RC systems ... cold traps and a wide selection of ...
... Acid Resistant SpeedVac Model SPD131DDA , Our ... SPD131DDA is designed to handle the rigors and ... slim design, digital display, dual independent timers, an ... chamber and vapor pathway. , , Adjustable ...
...
For absolute protein quantification. 4 peptides in 5 vials x 2 nmol per peptide...
Biology Products: